252882-60-3

Usage

Uses

Used in Pharmaceutical Research and Development:
1,2-Dihydro-2-oxo-spiro[3H-indole-3,4'-piperidine]-1'-carboxylic acid 1,1-dimethylethyl ester is used as a research compound for its potential biological activity. Its unique molecular structure allows it to interact with specific biological targets, making it a valuable tool in drug discovery and development.
Used in Drug Discovery:
In the field of drug discovery, 1,2-Dihydro-2-oxo-spiro[3H-indole-3,4'-piperidine]-1'-carboxylic acid 1,1-dimethylethyl ester is used as a lead compound. Its ability to bind to specific biological targets makes it a promising candidate for the development of new therapeutic agents.
Used in Chemical Industry:
1,2-Dihydro-2-oxo-spiro[3H-indole-3,4'-piperidine]-1'-carboxylic acid 1,1-dimethylethyl ester is also used in the chemical industry due to its stability and unique properties. The 1,1-dimethylethyl ester group contributes to the compound's stability, making it suitable for various applications in chemical synthesis and formulation.

Upstream product

• 59-48-3 2-oxoindole 
• 118753-70-1 N-(tert-butyloxycarbonyl)bis(2-chloroethyl)amine 
• 1151786-48-9 1-benzyl-1'-(tert-butoxycarbonyl)-5-fluoro-2,3-dihydrospiro[(2-oxo)-indole-3,4'-piperidine] 
• 615-36-1 2-bromoaniline 
• 84358-13-4 N-[(tert-butoxy)carbonyl]piperidine-4-carboxylic acid 
• 293744-31-7 tert-butyl 4-{[(benzyl)(2-bromophenyl)amino]carbonyl}piperidine-1-carboxylate 
• 293744-26-0 tert-butyl 4-{[(2-bromophenyl)amino]carbonyl}piperidine-1-carboxylate 
• 1086063-19-5 1'-benzylspiro[indoline-3,4'-piperidin]-2-one 
• 252882-61-4 spiro[indoline-3,4'-piperidin]-2-one 
• 24424-99-5 di-tert-butyl dicarbonate 
• 293744-34-0 tert-butyl 1-benzyl-1,2-dihydro-2-oxospiro[3H-indole-3,4'-piperidine]-1'-carboxylate 

Downstream Products

• 1086282-01-0 tert-butyl 2-oxo-1-(biphenyl-4-yl)-1,2-dihydro-1'H-spiro[indole-3,4-piperidine]-1'-carboxylate 
• 873779-30-7 1'-Boc-5-bromo-1,2-dihydro-2-oxo-spiro[3H-indole-3,4'-piperidine] 
• 356072-46-3 spiro[indoline-3,4’-piperidine]-2-one hydrochloride 
• 1086282-13-4 tert-butyl 1-biphenyl-4-yl-2'-[methoxy(oxo)acetyl]-2-oxo-1,2-dihydro-1'H-spiro[indole-3,4'-piperidine]-1'-carboxylate 
• 1086280-00-3 1-biphenyl-4-yl-1'-[(1-methyl-1H-imidazol-2-yl)methyl]spiro[indole-3,4'-piperidin]-2(1H)-one 
• 1426689-06-6 C₂₄H₂₆BrFN₂O₃ 
• 293744-34-0 tert-butyl 1-benzyl-1,2-dihydro-2-oxospiro[3H-indole-3,4'-piperidine]-1'-carboxylate 
• 916445-11-9 1-benzyl-spiro[indoline-3,4'-piperidin]-2-one 
• 1215121-49-5 1,3-dihydro-1-phenyl-2H-indol-2-one 
• 1086282-02-1 C₂₄H₂₂N₂O 

Relevant academic research and scientific papers

PYRIDYL PIPERIDINES

The invention provides novel substituted pyridyl piperidine compounds according to Formula (I) which are Wnt pathway inhibitors, their manufacture and use for the treatment of hyperproliferative diseases such as cancer, inflammatory or degenerative diseases.

RSV ANTIVIRAL COMPOUNDS

Inhibitors of RSV replication of formula RI including stereochemically isomeric forms, and salts or solvates thereof, wherein R22, W, Q, V, Z p,s,and Het have the meaning as defined herein. The present invention also relates to processes for preparing said compounds, pharmaceutical compositions containing them and their use, alone or in combination with other RSV inhibitors, in RSV therapy.

1,3,8-triazaspiro[4.5]decane-2,4-diones as efficacious pan-inhibitors of hypoxia-inducible factor prolyl hydroxylase 1-3 (HIF PHD1-3) for the treatment of anemia

The discovery of 1,3,8-triazaspiro[4.5]decane-2,4-diones (spirohydantoins) as a structural class of pan-inhibitors of the prolyl hydroxylase (PHD) family of enzymes for the treatment of anemia is described. The initial hit class, spirooxindoles, was identified through affinity selection mass spectrometry (AS-MS) and optimized for PHD2 inhibition and optimal PK/PD profile (short-acting PHDi inhibitors). 1,3,8-Triazaspiro[4.5]decane-2,4-diones (spirohydantoins) were optimized as an advanced lead class derived from the original spiroindole hit. A new set of general conditions for C-N coupling, developed using a high-throughput experimentation (HTE) technique, enabled a full SAR analysis of the spirohydantoins. This rapid and directed SAR exploration has resulted in the first reported examples of hydantoin derivatives with good PK in preclinical species. Potassium channel off-target activity (hERG) was successfully eliminated through the systematic introduction of acidic functionality to the molecular structure. Undesired upregulation of alanine aminotransferese (ALT) liver enzymes was mitigated and a robust on-/off-target margin was achieved. Spirohydantoins represent a class of highly efficacious, short-acting PHD1-3 inhibitors causing a robust erythropoietin (EPO) upregulation in vivo in multiple preclinical species. This profile deems spirohydantoins as attractive short-acting PHDi inhibitors with the potential for treatment of anemia.

ANTAGONISTS OF PGD2 RECEPTORS

Described herein are compounds and pharmaceutical compositions containing such compounds that antagonize the PGD2 activated chemoattractant receptor-homologous molecule expressed on TH2 cells (CRTH2). Also described herein are methods of using such CRTH2 antagonists, alone and in combination with other compounds, for treating respiratory, cardiovascular, and other PGD2-dependent or PGD2 mediated conditions or diseases.

SPIROINDALONES

The present invention relates to spiroindalone compounds useful as HIF prolyl hydroxylase inhibitors to treat anemia and like conditions.

FUSED AND SPIROCYCLE COMPOUNDS AND THE USE THEREOF

The invention relates to fused and spirocycle compounds of Formula (I), or a pharmaceutically acceptable salt, prodrug, or solvate thereof, wherein R1, R2, Q1-Q3, and Z are defined as set forth in the specification. The invention is also directed to the use of compounds of Formula (I) to treat, prevent or ameliorate a disorder responsive to the blockade of calcium channels, and particularly N-type calcium channels. Compounds of the present invention are especially useful for treating pain.

ALPHA ARYL OR HETEROARYL METHYL BETA PIPERIDINO PROPANAMIDE COMPOUNDS AS ORL1-RECEPTOR ANTAGONIST

This invention provides the compounds of formula (I): or a pharmaceutically acceptable ester of such compound, or a pharmaceutically acceptable salt thereof, wherein Ri and R2 independently represent a hydrogen atom or the like; R3 represents a hydrogen atom, or the like; R4 represents a hydrogen atom or the like; (formula II) represents one of the following or the like; R5 represents an aryl group having from 6 to 10 ring atoms or the like; X represents an oxygen atom, or the like; Y represents an oxgen atom or the like and n represents an integer 0, 1 or 2. These compounds have ORL1-receptor antagonist activity; and therefore, are useful to treat diseases or conditions such as pain, various CNS diseases etc.

Inhibitors of prenyl-protein transferase

The present invention is directed to conformationally constrained compounds which inhibit prenyl-protein transferase and the prenylation of the oncogene protein Ras. The invention is further directed to chemotherapeutic compositions containing the compounds of this invention and methods for inhibiting prenyl-protein transferase and the prenylation of the oncogene protein Ras.